Cancer Prevention

Cancer Prevention A recent letter in The Scientist recommended greater emphasis on cancer prevention, and outlined personal and societal regimens to enhance prevention.1 While these recommendations are laudable, they have been known for years, but have essentially not been implemented. In the United States, and increasingly in many other countries, an illness sub-economy has developed. It goes by the misnomer of 'health care.' A substantial and increasing share of gross domestic product is

Written byRonald Kostoff
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

A recent letter in The Scientist recommended greater emphasis on cancer prevention, and outlined personal and societal regimens to enhance prevention.1 While these recommendations are laudable, they have been known for years, but have essentially not been implemented.

In the United States, and increasingly in many other countries, an illness sub-economy has developed. It goes by the misnomer of 'health care.' A substantial and increasing share of gross domestic product is devoted to all aspects of chronic illness and its supporting infrastructure, including:

As a first step, the healing communities (orthodox and alternative) need to reach consensus on the causes of, and preventive steps for, chronic illnesses of various types. This step is critical for credibility and eventual public acceptance. Many causes of cancer often take decades to identify and verify. Much of the data is 'soft.' While controlled experiments are possible with animal models over lengthy time periods, experience ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies